ClinicalTrials.gg
CompletedNCT02237157Updated May 7, 2021Results posted

A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

A Phase 1 interventional study of Gemcitabine, local delivery in Pancreatic Cancer, sponsored by RenovoRx. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-07.

Sponsored by RenovoRx · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies testing gemcitabine in Pancreatic Neoplasms — 29 open to participants now, 44 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.

Enrollment
247th of 352
20 · median 37
Started
2015
with 19 others
Phase 1
87 of 369
1 open now
Registered
259th of 369
by date

Among the 369 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 247th largest by enrollment of the 352 interventional ones that give a count, is one of 20 that started in 2015, is one of 87 in phase 1, and was the 259th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

29 of the 369 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies testing gemcitabine in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.

Read the detailed description

Patients diagnosed with unresectable pancreatic cancer who may or may not have had prior chemotherapy or radiation therapy may be eligible to enroll in this dose escalation study to determine the maximum tolerated dose of gemcitabine to be delivered locally to the pancreatic tumors using the RenovoCath R120 catheter. Patients enrolled may receive up to 8 catheterizations for delivering gemcitabine directly to the pancreatic tumors starting at a reduced dose( 1/4 of standard i.v. gemcitabine dose), then every two doses, increase the dose by 25% if there are no toxicities up to a maximum dose of 1000 mg/m2. There are four cycles, with two doses per cycle. Imaging studies will be conducted as well as assessment for standard, myelosuppresive and gastric toxicities will be assessed. Pain will also be measured throughout the study.

03

Conditions studied

  • Pancreatic Cancer

Keywords

  • pancreatic cancer
  • unresectable
  • gemcitabine
  • device
  • local delivery
  • chemoembolization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be eligible to participate in the study if all of the following criteria are met:

  1. Males and female subjects 18 years of age and older.
  2. Subjects with locally advanced unresectable adenocarcinoma (cytological or histologic proof required) of the pancreas.. Patients with islet cell tumors are not eligible.
  3. No clinical evidence of distant , excluding single liver metastasis and local lymph node involvement. Patients with more than a single liver metastasis and/or other metastases who have already failed systemic chemotherapy and/or are on a break from systemic chemotherapy who are not surgical candidates can also qualify for this study.
  4. Performance Status (KPS) >60.
  5. Adequate renal, and bone marrow function described as:

    1. Leukocytes ≥ 3,000/uL
    2. ≥ 1,500/uL
    3. ≥100,000/uL
    4. Serum creatinine ≥2.0 mg/dL. Creatinine less than or equal to 1.5 mg/dL or greater than 40 mL/min/1.73 m2 for patients with creatinine levels above institutional normal, as calculated by the Cockcroft Gault formula.
    5. ≥8.5 g/dL (may be receiving supportive therapy)
    6. PT/ (WNL)
  6. Adequate Hepatic function (endoscopic or percutaneous drainage as needed) described as:

    1. Total ≤3 times UNL (less than or equal to 2 mg/dL)
    2. (SGOT)/ALT (SGPT) ≤ 5 times or ≤5 times ULN in the setting of liver metastases.
    3. Lipase and Amylase within normal limits.
  7. Capable of understanding the purpose and risks of the study and willing to provide written and to comply with the procedures

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from participation in the study if any of the following criteria are met:

  1. Have a known sensitivity to gemcitabine.
  2. Identification of disease, with the exception of single liver metastases or local lymph node involvement. Patients with more than a single liver metastasis and/or other metastases who have already failed systemic chemotherapy and/or are on a break from systemic chemotherapy who are not surgical candidates can also qualify for this study.
  3. Evidence of coagulopathy.
  4. Inability or unwillingness to comply with study procedures and/or follow-up procedures.
  5. Evidence of infection or other coexisting medical condition, which in the opinion of the investigator would preclude administration of gemcitabine.
  6. Patients with uncontrolled congestive heart failure, unstable angina and myocardial infarction within 3 months.
  7. Female patient who is pregnant, nursing or planning on becoming pregnant.
  8. Current enrollment and participation in another clinical study or prior exposure to an agent within 12 weeks or 5 half-lives (whichever is longer) of anticipated dosing on Day 1 of this study.
  9. Have known .
  10. Have had any major surgery within four weeks of enrollment.
  11. Have any clinically detectable ascites.
  12. Have uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  13. Have serious medical or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  14. Other invasive within the past 3 years (with the exception of non-melanoma skin cancers, non-invasive bladder cancer or prostate cancer) not approved by the Medical Monitor (contact MM in event of prior diagnosis with malignancy to discuss enrollment status).
  15. Have had any chemotherapy or systemic within 2 weeks of study entry.
  16. Have acquired, hereditary or congenital immunodeficiency's including cellular immunodeficiencies, hypogammaglobulinemia and dysgammaglobulinemia or hepatitis.
  17. Have a prior history of a documented hemolytic event.
  18. Is -positive or Hepatitis positive.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Other
    Gemcitabine, Local Delivery (Dose 1)

    Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose

    Drug: Gemcitabine, local delivery

  • Other
    Gemcitabine, Local Delivery (Dose 2)

    Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose

    Drug: Gemcitabine, local delivery

  • Other
    Gemcitabine, Local Delivery (Dose 3)

    Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose

    Drug: Gemcitabine, local delivery

  • Other
    Gemcitabine, Local Delivery (Dose 4)

    Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose

    Drug: Gemcitabine, local delivery

Interventions

06

What researchers measure

Primary outcomes

  1. Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas

    Maximum Tolerated Dose (MTD) of gemcitabine administered intra-arterially to the pancreatic tumor(s) using the RenovoCath™ RC120 catheter. One week post treatment, toxicities will be assessed to determine if there is a pre-defined Dose Limiting Toxicity necessitating dose stopping or holding.

    Time frame: 1 week post treatment

Secondary outcomes

  1. CA19-9 Tumor Reduction

    Measurements of CA19-9 tumor marker are measured pre-treatment and at various time points (starting with one week) post treatment.

    Time frame: 1 week after treatment

07

Results

Posted May 7, 2021

Participant flow

Gemcitabine, Local Delivery (Dose 1)
Participant flow — Gemcitabine, Local Delivery (Dose 1)
MilestoneGemcitabine, Local Delivery (Dose 1)Gemcitabine, Local Delivery (Dose 2)Gemcitabine, Local Delivery (Dose 3)Gemcitabine, Local Delivery (Dose 4)
Started20000
Completed16000
Not completed4000
Withdrew: Adverse event3000
Withdrew: Withdrawal by subject1000
Gemcitabine, Local Delivery (Dose 2)
Participant flow — Gemcitabine, Local Delivery (Dose 2)
MilestoneGemcitabine, Local Delivery (Dose 1)Gemcitabine, Local Delivery (Dose 2)Gemcitabine, Local Delivery (Dose 3)Gemcitabine, Local Delivery (Dose 4)
Started01500
Completed01500
Not completed0000
Gemcitabine, Local Delivery (Dose 3)
Participant flow — Gemcitabine, Local Delivery (Dose 3)
MilestoneGemcitabine, Local Delivery (Dose 1)Gemcitabine, Local Delivery (Dose 2)Gemcitabine, Local Delivery (Dose 3)Gemcitabine, Local Delivery (Dose 4)
Started00110
Completed00110
Not completed0000
Gemcitabine, Local Delivery (Dose 4)
Participant flow — Gemcitabine, Local Delivery (Dose 4)
MilestoneGemcitabine, Local Delivery (Dose 1)Gemcitabine, Local Delivery (Dose 2)Gemcitabine, Local Delivery (Dose 3)Gemcitabine, Local Delivery (Dose 4)
Started0008
Completed0008
Not completed0000

Outcome measures

PrimaryDetermine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas

Maximum Tolerated Dose (MTD) of gemcitabine administered intra-arterially to the pancreatic tumor(s) using the RenovoCath™ RC120 catheter. One week post treatment, toxicities will be assessed to determine if there is a pre-defined Dose Limiting Toxicity necessitating dose stopping or holding.

Time frame:
1 week post treatment
Reported as:
Number · mg/m^2
Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas
mg/m^2Gemcitabine, Local Delivery
Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas1000
SecondaryCA19-9 Tumor Reduction

Measurements of CA19-9 tumor marker are measured pre-treatment and at various time points (starting with one week) post treatment.

Time frame:
1 week after treatment

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were collected during the treatment period, an average of 2.5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine, Local Delivery (Dose 1)0/20 (0%)5/20 (25%)7/20 (35%)
Gemcitabine, Local Delivery (Dose 2)0/15 (0%)4/15 (26.7%)7/15 (46.7%)
Gemcitabine, Local Delivery (Dose 3)0/11 (0%)3/11 (27.3%)4/11 (36.4%)
Gemcitabine, Local Delivery (Dose 4)0/8 (0%)2/8 (25%)0/8 (0%)
Most frequent serious events
Most frequent serious events
EventGemcitabine, Local Delivery (Dose 1)Gemcitabine, Local Delivery (Dose 2)Gemcitabine, Local Delivery (Dose 3)Gemcitabine, Local Delivery (Dose 4)
Pain - Abdominal (NOS)Gastrointestinal disorders0/200/150/111/8
SepsisBlood and lymphatic system disorders2/200/150/111/8
Intraoperative Arterial Injury / DissectionInjury, poisoning and procedural complications1/201/151/110/8
Intraoperative Arterial Injury - Lower ExtremityInjury, poisoning and procedural complications0/200/151/110/8
Respiratory FailureRespiratory, thoracic and mediastinal disorders0/200/151/110/8
DehydrationMetabolism and nutrition disorders0/201/150/110/8
Duodenal ObstructionInjury, poisoning and procedural complications0/201/150/110/8
GastritisGastrointestinal disorders0/201/150/110/8
Cardiac arrestCardiac disorders1/200/150/110/8
InfectionInfections and infestations1/200/150/110/8
Most frequent other events
Showing 10 of 11
Most frequent other events
EventGemcitabine, Local Delivery (Dose 1)Gemcitabine, Local Delivery (Dose 2)Gemcitabine, Local Delivery (Dose 3)Gemcitabine, Local Delivery (Dose 4)
FatigueGeneral disorders1/202/151/110/8
VomitingGastrointestinal disorders0/202/151/110/8
FeverGeneral disorders0/201/151/110/8
Median arcuate ligament syndromeMusculoskeletal and connective tissue disorders0/200/151/110/8
NauseaEar and labyrinth disorders1/201/150/110/8
Vasovagal episodeVascular disorders0/201/150/110/8
Arterial spasmVascular disorders1/200/150/110/8
ChillsGeneral disorders1/200/150/110/8
IncontinenceGastrointestinal disorders1/200/150/110/8
Intraoperative arterial injury - lower extremityInjury, poisoning and procedural complications1/200/150/110/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Gemcitabine, Local Delivery
<=18 years0
Between 18 and 65 years9
>=65 years11
Age, Continuous
Age, Continuous(years)Gemcitabine, Local Delivery
Median67.5 ± 9.72
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine, Local Delivery
Female11
Male9
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Gemcitabine, Local Delivery
Hispanic or Latino1
Not Hispanic or Latino18
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Gemcitabine, Local Delivery
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White17
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Gemcitabine, Local Delivery
United States20
08

Study locations

2 sites
  • El Camino Hospital, Oncology
    Mountain View, California 94040, United States
  • Florida Hospital
    Tampa, Florida 33613, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2021, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2014
First posted
Sep 11, 2014
Start
Mar 2015
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Results first posted
May 7, 2021
Last update
May 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02237157
Lead sponsor
RenovoRx
Responsible party
Sponsor
First posted
Sep 11, 2014
Start date
Mar 2015
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
May 7, 2021
Last update
May 7, 2021

Study contacts

Jiali Li, MD
principal investigator · El Camino Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion